Clincosm LogoSign in Get a demo

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Sponsor
Yongsheng Wang (Other)
Overall Status
Recruiting
CT.gov ID
NCT05809024
Collaborator
Jiangsu HengRui Medicine Co., Ltd. (Industry)
100
Enrollment
1
Location
1
Arm
36.8
Anticipated Duration (Months)
2.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker
Actual Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 25, 2025
Anticipated Study Completion Date :
Mar 25, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: single Arm

Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if ki67 was higher than 10% after two weeks,CDK4/6 Inhibitor was added.

Drug: letrozole
Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
Other Names:
  • CDK4/6 Inhibitor

    		•

    Outcome Measures

    Primary Outcome Measures

    1. ki67 index [Up to approximately 2 weeks]

      Independent review committee (IRC) evaluates the Ki67 index after treatment. Ki67 index using the definition of HE stained breast cancer samples after neoadjuvant therapy and surgery. (Defined by the American Joint Committee onCancer, AJCC).

    Secondary Outcome Measures

    1. Objective Overall Response Rate [Up to approximately 7 weeks]

      Defined as the proportion of subjects who achieved CR or PR as optimal tumor response during neoadjuvant therapy. Objective response rates will be assessed according to the RECIST v1.1 for the evaluation of efficacy in solid tumors.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Newly treated female patients, ≥18 and ≤75 years;

    2. ECOG score 0-1;

    3. Breast cancer following:

    Histologically confirmed invasive breast cancer with primary tumor diameter >2 cm by standard evaluation methods.Tumor stage: cT2-cT4/cN0-cN3/cM0 (clinical phase II and III)

    1. HR+/HER2- breast cancer confirmed by pathological examination, defined as: primary HR+/HER2- breast cancer performed by the pathology department of the Central Hospital;

    2. Get hormone receptor status (ER and PR);

    3. Major organ function following:

    Complete blood count: Neutrophil (ANC) ≥ 1.5×109/L; Platelet count (PLT) ≥ 90×109/L; hemoglobin (Hb) ≥90 g/L; Blood Biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) ≤ 1.5×ULN; Aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Urea nitrogen (BUN) ≤ 1.5×ULN; Creatinine (Cr) ≤ 1.5×ULN; Twelve-lead electrocardiogram: Fridericia corrected QT Interval (QTcF) woman < 470 ms (QTcF=QT/(RR^1/3));

    1. Woman who are not menopausal or have not been surgically sterilized agree to abstain from sex or use effective contraceptive methods for at least the duration of the study treatment and for 7 months after the last dosing;

    2. Volunteer to participate in the study, sign informed consent, have good compliance and be willing to cooperate with follow-up.

    Exclusion Criteria:

    1. IV stage breast cancer or metastatic breast cancer;

    2. Inflammatory breast cancer;

    3. Any previous malignant tumor or previous anti-tumor therapy or radiotherapy were not allowed, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;

    4. Participate in other clinical trials;

    5. Patients were not allowed who had undergone major non-breast cancer related surgery within 4 weeks prior to randomization or had not fully recovered from such surgery;

    6. Patients were not allowed who had received blood transfusion or colony stimulating factor treatment within 2 weeks before randomization;

    7. Patients were not allowed who allergic to drug components;

    8. Patients were not allowed who had a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;

    9. Patients have heart disease were not allowed including: (1) angina pectoris; (2) medically treatable or clinically significant arrhythmias; (3) myocardial infarction; (4) heart failure; (5) any other heart disease that the investigator has determined is not suitable for participation in the study;

    10. Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or fertile women who were unwilling to take effective contraceptive measures during the test period were not allowed;

    11. Patients have concomitant diseases that endanger patient safety or influence the completion of the study were not allowed (including but not limited to hypertension, severe diabetes, active infection, thyroid disease, etc.);

    12. Patients were not allowed who with inability to swallow, chronic diarrhea and intestinal obstruction, accompany multiple factors affecting the administration and absorption of medicines;

    13. Any other circumstances in which the investigator considers the patients unsuitable for participation in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Breast Cancer Center, Shandong Cancer Hospital and Institute Jinan Shandong China 250117

    Sponsors and Collaborators

    • Yongsheng Wang
    • Jiangsu HengRui Medicine Co., Ltd.

    Investigators

    • Principal Investigator: yongsheng wang, Shandong Cancer Hospital and Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yongsheng Wang, Director of breast cancer center, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital and Institute
    ClinicalTrials.gov Identifier:
    NCT05809024
    Other Study ID Numbers:
    • MA-BC-II-023
    First Posted:
    Apr 12, 2023
    Last Update Posted:
    Apr 12, 2023
    Last Verified:
    Apr 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:
    Breast Neoplasms
    Letrozole

    Study Results

    No Results Posted as of Apr 12, 2023